InVivoMab anti-Influenza A virus NP BE0159-R001mg from Bio X Cell

Description

Bio X Cell InVivoMAb anti-Influenza A virus NP Monoclonal Antibody has the following reported applications: Immunoprecipitation, Immunohistochemistry (paraffin), in vivo induction of passive immunity to influenza A virus, Western blot, Flow cytometry. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMab anti-Influenza A virus NP
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0159-R001mg
Quantity1 mg
ApplicationsImmunoprecipitation, Immunohistochemistry (paraffin), in vivo induction of passive immunity to influenza A virus, Western blot, Flow cytometry
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityVirus
TargetInfluenza A NP
IsotypeIgG2a
CloneH16-L10-4R5 (HB-65)
Hostmouse
ClonalityMonoclonal
ImmunogenMediastinal lymphocytes from BALB/c mice infected with influenza A virus
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Phosphorylation controls RNA binding and transcription by the influenza virus polymerasePLoS pathogensSeptember 1, 2020Dawson AR, Wilson GM, Freiberger EC, Mondal A, Coon JJ, Mehle A.

(2) A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in MiceMolecular therapy : the journal of the American Society of Gene TherapyJuly 8, 2020Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, Tam YK, Madden TD, de Souza Ferreira LC, Weissman D, et al.

(3) Oligomerization and GTP-binding Requirements of MxA for Viral Target Recognition and Antiviral Activity against Influenza A VirusThe Journal of biological chemistryDecember 11, 2015Nigg PE, Pavlovic J.

(4) Highly pathogenic avian influenza A H5N1 and pandemic H1N1 virus infections have different phenotypes in Toll-like receptor 3 knockout miceThe Journal of general virologySeptember 1, 2014Leung YH, Nicholls JM, Ho CK, Sia SF, Mok CK, Valkenburg SA, Cheung P, Hui KP, Chan RW, Guan Y, et al.

(5) Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus cultureJournal of clinical microbiologyMay 1, 2014van Baalen CA, Els C, Sprong L, van Beek R, van der Vries E, Osterhaus AD, Rimmelzwaan GF.

(6) Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infectionsJournal of immunology (Baltimore, Md. : 1950)November 15, 2012Haynes L, Szaba FM, Eaton SM, Kummer LW, Lanthier PA, Petell AH, Duso DK, Luo D, Lin JS, Lefebvre JS, et al.

Be the First to Write a Review!